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Abstract 
Background: The aim of the study was to compare clinical characteristics of real-life AF 
patients with populations included in randomized clinical trials (ROCKET AF and RE-LY).   
Methods: The analysis included 3528 patients who are participants of the ongoing, 
multicentre, retrospective CRAFT study. The study is registered in ClinicalTrials.gov: 
NCT02987062. The study is based on a retrospective analysis of hospital records of AF 
patients treated with vitamin K antagonists (VKAs) (acenocoumarol, warfarin) and non-
vitamin K oral anticoagulants (NOACs) (dabigatran, rivaroxaban). CHADS2 score was used 
for risk of stroke stratification.  
Results: VKA was prescribed in 1973 (56.0%), while NOAC in 1549 (44.0%), including 
dabigatran — 504 (14.3%) and rivaroxaban — 1051 (29.8%), of the 3528 patients. VKA 
patients in the CRAFT study were at significantly lower risk of stroke (CHADS2 1.9 ± 1.3), 
compared with the VKA population from the RE-LY (2.1 ± 1.1) and the ROCKET-AF (3.5 ± 
1.0). Patients in the CRAFT study treated with NOAC (CHADS2 for patients on dabigatran 
 2 
150 mg — 1.3 ± 1.2 and on rivaroxaban — 2.2 ± 1.4) had lower risk than pts from the RE-
LY (2.2 ± 1.2) and the ROCKET AF (3.5 ± 0.9).  
Conclusions: Real-world patients had a lower risk of stroke than patients included in the RE-
LY and ROCKET AF trials. 
Key words: non-valvular atrial fibrillation, oral anticoagulation, randomized trial, real-
world study 
 
 
Introduction 
Atrial fibrillation (AF) is an increasingly common cardiac arrhythmia which affects 
3% of adults in the European population [1]. It is related to the ageing of modern societies 
and its prevalence is increasing with a presence of certain comorbidities (i.e. hypertension, 
coronary artery disease, heart failure) [1, 2]. A key element of AF patient management is 
anticoagulation to prevent thromboembolic events, especially AF-related stroke, which is 
combined with poor outcomes and high total costs [1]. According to the current European 
Society of Cardiology (ESC) guidelines for non-valvular AF treatment, the first line drugs are 
non-vitamin K oral anticoagulants (NOACs), which are preferred over vitamin K antagonists 
(VKA) [1]. NOACs were shown to be at least as effective and safer than VKAs for stroke 
prevention in patients with non-valvular AF [1]. However, it is not clearly confirmed, how 
the success of NOACs’ approval trials — ROCKET AF (rivaroxaban), RE-LY (dabigatran 
etexilate), and ARISTOTLE (apixaban) may reflect on real-life clinical practice.   
The aim of the study was to compare clinical characteristics of real-life AF patients 
with populations included in randomized clinical trials (ROCKET AF and RE-LY).   
 
Methods 
The analysis was based on multicenter, retrospective CRAFT (MultiCenter 
expeRience in AFib patients Treated with OAC) study, registered in ClinicalTrials.gov: 
NCT02987062 [3]. The CRAFT study was conducted at two cardiology centers in Poland, 
academic center located in capital city and district hospital. The study was approved by a 
local ethical review board. 
 
Study design and population 
The CRAFT study retrospectively included all patients hospitalized in the years 
between 2011–2016 with diagnosis of non-valvular AF and treated with one of the oral 
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anticoagulants (OAC) — VKAs (acenocoumarol, warfarin) and NOAC (apixaban, 
dabigatran, rivaroxaban). Patients were 18 years of age and older. There were no other 
specific inclusion or exclusion criteria. Patients on apixaban were excluded due to a small 
number in this group . Another NOAC — edoxaban was not available on the Polish market at 
the time of data collection. The data about patient characteristics was gathered retrospectively 
from hospital records.  
 
Design of the randomized trials 
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) study 
was a multicenter, randomized trial designed to compare two fixed doses of dabigatran (110 
mg or 150 mg) with adjusted-dose warfarin [4]. The Rivaroxaban Once Daily Oral Direct 
Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and 
Embolism Trial in Atrial Fibrillation (ROCKET AF) was a multicenter, randomized, double-
blind trial, in which patients were randomly assigned to receive a fixed dose rivaroxaban (20 
mg daily or 15 mg daily in patients with a creatinine clearance of 30 to 49 mL per minute) or 
adjusted-dose warfarin [5]. In both trials patients with non-valvular AF documented on 
electrocardiography who were at increased risk of stroke, which was defined as history of 
previous stroke or transient ischemic attack (TIA) or systemic embolism, older age, 
coexistence of comorbidities such as heart failure with reduced ejection fraction, 
hypertension, diabetes mellitus or coronary artery diseases were randomized to different 
study arms. Complete inclusion and exclusion criteria are described in trial protocols [5, 6]. 
The main exclusion criteria are shown in Table 1.  
 
Comparative analysis of patients treated with OAC — randomized trials vs real-world 
patients 
In the current analysis, patients were divided into four groups according to the type of 
OAC (VKA, dabigatran 110 mg, dabigatran 150 mg, rivaroxaban 15 or 20 mg). Investigators 
compared clinical characteristics of real-life AF patients from the CRAFT study with 
populations included in the randomized clinical trials (ROCKET AF and RE-LY). Patients 
were compared in terms of baseline characteristics regarding demographics, medical history, 
type of AF (paroxysmal, persistent or permanent), diagnostic test results and co-
pharmacotherapy. Thromboembolic risk of each group was compared using CHADS2 
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(Congestive heart failure, Hypertension, Age ≥ 75, Diabetes, Stroke [doubled]) score which 
was used in the ROCKET AF and RE-LY trials.  
 
Statistical analysis 
Statistical analyses were performed using SPSS software, version 22 (IBM SPSS 
Statistics 22, USA, New York). Normally distributed continuous variables were presented as 
mean values and standard deviations, while ordinal variables and non-normally distributed 
continuous variables, as median values and interquartile ranges (IQR). Categorical data is 
presented as a number of patients and percentages. The significance of differences between 
groups was determined by the Fisher exact test for categorical variables and Mann-Whitney 
U test for continuous and ordinal variables, respectively. P-values less than 0.05 were 
considered significant. All tests were two-tailed.  
 
Results 
Characteristics of the study patients 
A comparison of clinical characteristics of patients from the CRAFT, RE-LY and 
ROCKET AF studies are presented in Table 2. Table 3 presents thromboembolic risk factors 
in the study participants according to the treatment group. In both trials (RE-LY and 
ROCKET AF) patients with creatinine clearance < 30 mL per minute were excluded, while in 
the present study 2.7% of patients were below this threshold.  
 
CRAFT study 
A total of 3528 Caucasian patients were enrolled in the CRAFT study, of whom 1973 
(56.0%) were on VKAs and 1549 (44.0%) patients were on NOACs, including rivaroxaban 
— 1051 (29.8%) and dabigatran — 504 (14.3%). In the dabigatran group, 187 (5.3%) 
patients received 110 mg twice daily and 311 (8.8%) patients received 150 mg twice daily. 
There were 6 patients with missing data on the dabigatran dose. Patients on rivaroxaban 
received 15 mg or 20 mg once daily, but following the methodology from the ROCKET AF 
trial, both doses were analyzed collectively. Figure 1 shows the flow chart of patient selection 
in the current study. The mean age of the total population was 67.9 ± 13.2 years and 59.8% 
were male. Patients on dabigatran 110 mg were the oldest (75.8 ± 10.2 years). In the total 
population paroxysmal AF had 1820 (51.6%), permanent AF 955 (27.0%) and persistent 596 
(16.9%) patients. 
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RE-LY trial 
In the RE-LY study a total cohort of 18,113 patients were enrolled, including 6022 
patients on VKA, 6015 on dabigatran 110 mg and 6076 on dabigatran 150 mg. The mean age 
of the total cohort was 71 years and 63.6% were male [4]. 
 
ROCKET AF trial 
In the ROCKET AF study, a total of 14,264 patients were enrolled, including 7133 
patients on VKA and 7131 on rivaroxaban (15 or 20 mg dose). Reduced dose of rivaroxaban 
(15 mg once daily) was intended for patients with estimated creatinine clearance (CrCl) 30–
49 mL/min (calculated by the Cockroft-Gault formula). The mean age of the total cohort was 
73.0 ± 9.6 years and 60.3% were male [5]. 
 
Comparative analysis of patients treated with OAC — randomized trials vs real-world 
patients  
VKA patients. Patients on VKAs in the CRAFT study were younger (67.0 ± 12.8 
years) than patients from the RE-LY and ROCKET AF trials (71.6 ± 8.6 years, p < 0.0001; 
and 73.0 ± 9.6, p < 0.0001, respectively). Patients in the CRAFT study (similar to the RE-LY 
study) were more likely to be male (63.5%) than in the ROCKET AF (60.3%, p = 0.01). In 
the CRAFT study patients on VKAs had mainly paroxysmal AF (52.1%), in the ROCKET 
AF had persistent AF (80.8%), while in the RE-LY comparably often all types of AF. 
Patients in the present study had significantly lower risk of stroke (CHADS2 1.9 ± 1.3), 
compared with VKA population from RE-LY (2.1 ± 1.1) and ROCKET-AF (3.5 ± 1.0). A 
comparison of thromboembolic risk (assessed by CHADS2 score) of each group from 
CRAFT, RE-LY and ROCKET AF studies is presented in Figure 2. Patients on VKAs in the 
ROCKET AF trial more frequently had a history of stroke or TIA, heart failure, diabetes, 
hypertension and chronic pulmonary disease than in the CRAFT study. Whereas, patients 
from the RE-LY trial more frequently had a history of stroke or TIA and hypertension, but 
less frequently had heart failure or diabetes than in the CRAFT study.  
Dabigatran patients. Patients on dabigatran 110 mg in the CRAFT study were older 
(75.8 ± 10.2 years) and were less frequently male (56.1%), compared with patients on the 
same dose in the RE-LY trial (71.4 ± 8.6 years, p < 0.0001; 64.3%, p = 0.02). In the CRAFT 
study patients on dabigatran 110 mg had mainly paroxysmal AF (47.3%), while in the RE-
LY trial comparably often had all types of AF. There was no statistical significance in 
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comparison of permanent AF occurrence between CRAFT and RE-LY studies. Patients on 
dabigatran 110 mg in the CRAFT study were at higher risk of stroke (CHADS2 2.6 ± 1.2) 
compared with dabigatran 110 mg population from the RE-LY trial (2.1 ± 1.1). Patients on 
dabigatran 110 mg in the CRAFT study also had heart failure more frequently, but had 
similarly frequent previous stroke or TIA, diabetes and hypertension. 
Patients on dabigatran 150 mg in the CRAFT study were younger (60.0 ± 12.4 years), 
than patients on the same dose in the RE-LY trial (71.5 ± 8.8 years, p < 0.0001). In the 
CRAFT study patients on dabigatran 150 mg had mainly paroxysmal AF (59.7%), while in 
the RE-LY trial had mainly permanent AF (36.0%). Patients on dabigatran 150 mg in the 
CRAFT study had a lower risk of stroke (CHADS2 1.3 ± 1.2) when compared to patients 
from the RE-LY trial (2.2 ± 1.2). Patients on dabigatran 150 mg in the CRAFT study 
frequently had less previous stroke or TIA, heart failure, diabetes and hypertension than in 
the RE-LY trial. There was no difference with regard to sex and persistent AF occurrence 
between groups.  
Rivaroxaban patients. Patients on rivaroxaban in the CRAFT study were younger 
(70.5 ± 13.1 years) and less frequently male (52.1%), when compared with patients from the 
ROCKET AF trial (73.0 ± 9.6 years, p < 0.0001; 60.3%, p < 0.0001). In the CRAFT study 
patients on rivaroxaban more frequently had paroxysmal AF (57.3%), while in the ROCKET 
AF trial they had persistent AF (81.1%). Patients on rivaroxaban in the present study had a 
significantly lower risk of stroke (CHADS2 2.2 ± 1.4), compared with the population from 
ROCKET-AF (3.5 ± 0.9). Patients on rivaroxaban in the CRAFT study had previous stroke or 
TIA, heart failure, diabetes and hypertension less frequently than in the ROCKET AF trial, 
but more often had chronic obstructive pulmonary disease. 
 
Discussion 
Randomized controlled trials (RCT) are the gold standard for evaluation of therapy 
outcomes in terms of treatment efficacy and safety [7]. However, it needs to be emphasized 
that they have a limited generalizability because they are performed under very different 
conditions from a routine clinical practice [7]. Rigorous insight into those differences in 
patient characteristics may be important in interpreting results of RCT. Therefore, there is a 
need for real-life data to compare populations enrolled to RCT with patients from everyday 
clinical practice. It should however, be underlined that RCT and real-word studies are 
complementary. They provide data from different settings and both contribute to knowledge 
on AF patients. 
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Therapy with VKAs is found to be highly effective for stroke prevention in non-
valvular AF patients, however a proper monitoring and dose adjustment is challenging for 
physicians and patients [8, 9]. What is more, the efficacy and safety of VKAs depends on 
inter- and intra-individual variations, which are associated with food and drug interactions [8, 
9]. On the other hand, NOACs are available with no need for regular blood monitoring and 
have fewer interactions with other medications [10, 11]. However, one third of patients 
treated with NOACs appear to have disruptions in therapy, which are associated with 4–6-
fold increased risk of stroke or TIA [12]. The ESC guidelines for non-valvular AF treatment 
recommend NOACs as the first line drugs [1], especially for patients on VKAs with 
unsatisfactory individual time in therapeutic range (TTR). Data from smaller studies showed 
that NOACs are safe and effective in real-world non-valvular AF patients also in secondary 
stroke prevention [13–15]. 
Our understanding of rivaroxaban (direct oral factor Xa inhibitor) and dabigatran 
(direct thrombin inhibitor) efficacy and safety profiles mainly come from the two RCTs — 
ROCKET AF and RE-LY, respectively [4, 5]. In ROCKET AF rivaroxaban was non-inferior 
to warfarin in the prevention of stroke or systemic embolism, with no significant differences 
in incidence of overall bleeding events between groups, though it was associated with a lower 
rate of intracranial and fatal bleedings [5]. In the RE-LY trial, the 150-mg dose of dabigatran 
was associated with lower rates of stroke and systemic embolism, and a similar rate of major 
hemorrhage [4]. Whereas, the 110-mg dose of dabigatran was associated with similar rates of 
stroke and systemic embolism and lower rates of major hemorrhage [4]. 
Importantly, the CRAFT study revealed a lower incidence of previous stroke or TIA 
in the real-world, than was observed in the RCTs. The difference was especially remarkable 
in comparison with the ROCKET AF trial, where more than half of the population (54.9%) 
experienced previous stroke or TIA [5], while in the CRAFT study it was only 12.7%. The 
present results are not isolated, and they are in line with a recently performed prospective, 
observational Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS) 
study, where 19% of patients with non-valvular AF experienced previous stroke or TIA [16]. 
The aim of this study was to assess rivaroxaban in stroke prevention in real-life clinical 
practice. The mean age of the cohort in the XANTUS study was 71.5 ± 10 years, 41% were 
female and there was a higher proportion of paroxysmal AF [16], similar to the population of 
this study.  
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Patients in the CRAFT study had paroxysmal AF significantly more often, while 
patients in the RE-LY and ROCKET AF trials had more sustained forms [4, 5]. These results 
are in line with data from Atrial Fibrillation General Pilot registry conducted by ESC, which 
showed that Polish patients more often had paroxysmal AF (32.8%) than patients from other 
countries of the European Union (25.5%) [17]. It is known that more sustained forms of AF 
may be associated with increased symptoms and cardiovascular morbidity [18]. The 
prevailing frequency of paroxysmal AF and thus a lower burden of comorbidities, was 
probably associated with a lower estimated thromboembolic risk in patients from the CRAFT 
and XANTUS studies. Moreover, Gorczyca-Michta et al. [19] revealed that paroxysmal 
arrhythmia is a factor associated with an increased probability of NOAC prescription. 
In the CRAFT study patients had a lower risk of stroke (calculated by CHADS2 score) 
than patients included in the RE-LY and ROCKET AF trials, as showed in Figure 2. This was 
similarly observed in a retrospective REal-LIfe Evidence on stroke prevention in patients 
with atrial Fibrillation (RELIEF), a study evaluating the use of rivaroxaban in a German 
community [20]. In this study risk of stroke in non-valvular AF patients was similar to 
rivaroxaban (mean CHADS2 1.7) and VKA (mean CHADS2 1.8) patients as in the present 
study [20]. These data showed that real-world patients have a lower risk of stroke than 
patients included in RCT, especially when compared to the ROCKET AF trial. Nevertheless, 
as previously observed in the CRAFT study, there were differences in clinical characteristics 
of AF patients treated with OAC between the district and academic hospitals. Patients treated 
in an academic hospital were younger, had lower CHADS2, CHA2DS2VASc scores, had less 
comorbidities and a lower risk of bleeding complications than patients treated in the district 
hospital [21]. It should be noted, that a majority of the CRAFT population was recruited in an 
academic hospital and nearly 75% of this group patients were relatively low risk   and were 
admitted to hospital for AF ablation or cardioversion. 
However, in the ROCKET AF rivaroxaban failed to demonstrate a reduction in 
ischemic stroke in comparison to warfarin. One of the hypotheses had concerns that patients 
on VKA included in the ROCKET AF study had a mean TTR of approximately 63% [5, 22]. 
While, data from meta-analysis including patients from everyday practice suggested that real 
TTR is about 9% lower than in randomized selected patients [23]. Results herein suggest that 
in real-life clinical practice patients are healthier, with lower thromboembolic risk. 
Additionally, lower TTR may result in a worse effectiveness of VKA in real-life than was 
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shown in the ROCKET AF. These may translate into additional benefits from the use of 
NOACs in real-life clinical practice. 
Patients enrolled in the CRAFT study were younger and the prevalence of 
concomitant diseases was lower than in patients from the ROCKET AF trial, as well as the 
fact that patients were on dabigatran 150 mg in the RE-LY trial [4, 5]. Interestingly, in the 
CRAFT study only patients on dabigatran 110 mg had a higher risk of stroke (calculated 
using CHADS2 score) and had a similar frequency of previous stroke or TIA, compared to 
patients from the RE-LY trial [4]. This real-life cohort was older and had more comorbidities 
than groups on other anticoagulants. This probably reflects that physicians prescribe a lower 
dose of dabigatran for elderly and patients suffering from numerous concomitant diseases 
[24]. Lopatowska et al. [25] did a study based on 1556 real-life Polish AF patients, which 
observed that the use of OAC increased with higher CHA2DS2-VASc score of up to 3 points 
and surprisingly was less frequent in scores ≥ 4. However, Steinberg et al. [26] showed that 
elderly AF patients rarely have absolute contraindications to oral anticoagulation therapy 
albeit those who do are also at high risk for thromboembolic events. It may be a sign that in 
elderly, anticoagulation therapy is underutilized despite strong indications. Similarly, The 
Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) registry 
demonstrated some inaccuracies. Patients with a low risk of stroke had prescribed 
anticoagulants more often than needed, while patients with a high risk of stroke were left 
without this treatment [27]. Moreover, authors of a prospective observational REgistro 
POliterapie SIMI (REPOSI) study, based on in-patients aged ≥ 65 years, stressed that a 
proper adherence to the antithrombotic therapy guidelines, among elderly AF patients is 
associated with a lower risk for all cause and cardiovascular deaths [28]. 
In a real-life setting the educational level of patients also matters, more than in RCT. 
Knowledge about AF and its consequences, as well as the importance of uninterrupted 
anticoagulation therapy, influences adherence to the therapy. It was shown in the OCULUS 
study that the educational level of patients was unsatisfactory and may translate into further 
differences in stroke prevention effectiveness [29]. 
 
Limitations of the study 
The limitations mainly derive from the CRAFT study. First of all, the sample size was 
not representative of the whole population because data came from just two centers. It should 
be underlined that rivaroxaban and dabigatran groups enrolled in the CRAFT study were 
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more than ten times less populated than their RCTs counterparts, nonetheless the study 
included over 3500 patients.   
Importantly, based on inclusion criteria of RCT there was an imbalance of 
thromboembolic risk profile of patients between CRAFT and ROCKET AF studies. In the 
ROCKET AF trial, only patients with  moderate-to-high risk of stroke had been enrolled and, 
according to the protocol, the proportion of patients with a previous stroke or TIA, was 
brought up to 50% of the whole study population during the randomization process.  
Furthermore, there was no possibility to compare the risk of stroke using a more 
accurate and valid CHA2DS2-VASc classification, because this score was not used in the 
ROCKET AF or RE-LY trials. 
Additionally, a retrospective study may contain inaccuracies such as completeness of 
data or coding that can result in biases. Moreover, there were a limited number of patients 
and neither apixaban or edoxaban were available on the market, and were thus excluded from 
the analysis. 
 
Conclusions 
The CRAFT study showed that real-world patients demonstrated a distinct clinical 
profile compared to populations from the RE-LY and ROCKET AF trials. In general, real-
world patients had a lower risk of stroke and prevalence of comorbid diseases than patients 
included in the RE-LY and ROCKET AF trials. Only patients who received dabigatran 110 
mg in the CRAFT study were at higher risk of thromboembolic events than the same group in 
the RE-LY trial.  
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Table 1. The main exclusion criteria for the randomized trials. 
 
Exclusion criteria 
RE-LY ROCKET-AF 
1. History of heart valve disorder (i.e., 
prosthetic valve or hemodynamically 
relevant valve disease). 
2. Severe, disabling stroke within the previous 
6 months, or any stroke within the previous 
14 days. 
3. Conditions associated with an increased risk 
of bleeding (i.e. history of an active severe 
bleeding, major surgery within the previous 
month, planned surgery or intervention, 
uncontrolled hypertension, recent 
malignancy or radiation therapy). 
4. Anemia (hemoglobin level less than 100 g/L) 
or thrombocytopenia. 
5. Contraindication to warfarin treatment.  
6. Reversible causes of atrial fibrillation. 
7. Plan to perform a pulmonary vein ablation or 
surgery for cure of the atrial fibrillation.  
8. Severe renal impairment (estimated 
creatinine clearance 30 mL/min or less).  
9. Active liver disease. 
10. Active infective endocarditis.  
11. Women who are pregnant or of childbearing 
potential. 
1. Hemodynamically significant mitral valve stenosis. Prosthetic 
heart valve. 
2. Reversible causes of atrial fibrillation. Planned cardioversion. 
3. Known presence of atrial myxoma or left ventricular thrombus.  
4. Conditions associated with an increased risk of bleeding (i.e. 
history of an internal bleeding, planned invasive procedure, 
sustained uncontrolled hypertension). 
5. Anemia (hemoglobin < 10 g/dL), platelet count < 90,000/μL. 
6. Severe, disabling stroke within 3 months or any stroke within 14 
days. Transient ischemic attack within 3 days. 
7. Indication for anticoagulant therapy for a condition other than 
atrial fibrillation (e.g. venous thromboembolism). 
8. Treatment with: acetylsalicylic acid > 100 mg daily; or 
acetylsalicylic acid in combination with thienopyridines, 
intravenous antiplatelets or fibrinolytics within 10 days before 
randomization. 
9. Anticipated need for chronic treatment with a non-steroidal anti-
inflammatory drug. 
10. Drug addiction or alcohol abuse. 
11. Known allergy or hypersensitivity to any component of 
rivaroxaban, warfarin or placebo excipients. 
12. Calculated creatinine clearance < 30 mL/min. 
13. Known significant liver disease. 
14. Active endocarditis. 
15. Pregnancy or breast-feeding. 
The table was prepared based on trial protocols. 
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Table 2. Baseline characteristics of the study participants (from the CRAFT, RE-LY [2] and ROCKET AF studies [3]) according to the treatment 
group. 
Variable VKA  Dabigatran 110 mg  Dabigatran 150 mg  Rivaroxaban 15 or 20 mg  
 
CRAFT 
(n = 
1973) 
RE-LY (n 
= 6022) 
ROCKE
T AF (n 
= 7133) 
P* 
CRAFT 
(n = 187) 
RE-LY (n 
= 6015) 
P 
CRAFT (n = 
311) 
RE-LY (n 
= 6076) 
P 
CRAFT (n = 
1051) 
ROCKET AF 
(n = 7131) 
P 
Age [years] 
67.0 ± 
12.8 
71.6 ± 8.6 
73.0 ± 
9.6 
< 
0.0001 
< 
0.0001 
75.8 ± 
10.2 
71.4 ± 8.6 
< 
0.0001 
60.0 ± 12.4 71.5 ± 8.8 < 0.0001 70.5 ± 13.1 73.0 ± 9.6 
< 
0.0001 
Male sex 
1252 
(63.5) 
3809 
(63.3) 
4301 
(60.3) 
0.87 
0.01 
105 (56.1) 
3865 (64.3) 
0.02 198 (63.7) 3840 (63.2) 0.86 548 (52.1) 4300 (60.3) 
< 
0.0001 
BMI 
[kg/m2] 
29.6 ± 
6.3, n = 
125 
– 
28.1 ± 
5.0 0.001 
28.0 ± 5.4, 
n = 53 
–  
28.5 ± 4.8, n 
= 37 
–  
29.3 ± 4.9, n = 
146 
28.3±5.1 0.02 
Persistent 
AF 
351/1902 
(18.5) 
1930/6021 
(32.0) 
5762 
(80.8) 
< 
0.0001 
< 
0.0001 
28/182 
(15.4) 
1950/6011 
(32.4) 
< 
0.0001 
83/298 (27.9) 
1909/6075 
(31.4) 
0.20 
134/998 
(13.6) 
5786 (81.1) 
< 
0.0001 
Paroxysmal 
AF 
990/1901 
(52.1) 
2036/6021 
(33.8) 
1269 
(17.8) 
< 
0.0001 
< 
0.0001 
86/182 
(47.3) 
1929/6011 
(32.1) 
< 
0.0001 
178/298 
(59.7) 
1978/6075 
(32.6) 
 
< 0.0001 
566/987 
(57.3) 
1245 (17.5) 
< 
0.0001 
Permanent 
AF 
561/1902 
(29.5) 
2055/6021 
(34.1) 
– 0.0002 
68/182 
(37.4) 
2132/6011 
(35.4) 0.58 37/298 (12.4) 
2188/6075 
(36.0) 
< 0.0001 
289/988 
(29.3) 
–  
Aspirin 304 (15.4) 
2442/6017 
(40.6) 
2619 
(36.7) 
< 
0.0001 
< 
0.0001 
17/187 
(9.1) 
2404/6013 
(40.0) 
< 
0.0001 
13/311 (4.2) 
2352/6075 
(38.7) 
< 0.0001 88/1050 (8.4) 2586 (36.3) 
< 
0.0001 
ACEI or 
ARB 
1221/1632 
(74.8) 
3939/6017 
(65.5) 
– 
< 
0.0001 
82/108 
(75.9) 
3987/6013 
(66.3) 0.04 
157/244 
(64.3) 
4053/6075 
(66.7) 
0.44 
485/676 
(71.7) 
–  
BB 
1342/1631 
(82.3) 
3719/6017 
(61.8) 
– 
< 
0.0001 
88/108 
(81.5) 
3784/6013 
< 
0.0001 
182/244 
(74.6) 
3872/6075 
(63.7) 
< 0.0001 
540/676 
(79.9) 
–  
 15 
(62.9) 
Amiodarone 
162/1971 
(8.2) 
644/6017 
(10.7) 
– 0.001 
20/186 
(10.8) 
624/6013 
(10.4) 0.86 27/311 (8.7) 
665/6075 
(10.9) 
0.22 
110/1050 
(10.5) 
–  
Statin 
1046/1632 
(64.1) 
2673/6017 
(44.4) 
– 
< 
0.0001 
72/108 
(66.7) 
2698/6013 
(44.9) 
< 
0.0001 
120/244 
(49.2) 
2667/6075 
(43.9) 
0.10 
439/676 
(64.9) 
–  
Continuous variables are presented as mean ± standard deviation or number and (percentage). 
ACEI — angiotensin-converting enzyme inhibitor; AF — atrial fibrillation; ARB — angiotensin-receptor blocker; BB — beta-blocker; BMI — body mass index; n — 
number; RE-LY — The Randomized Evaluation of Long-Term Anticoagulation Therapy; ROCKET — Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared 
with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation, VKA — vitamin K antagonist 
*First p-value, (written above) refers to the comparison of VKA patients from the CRAFT and RE-LY studies, second p-value (written below) refers to the comparison of 
patients from the CRAFT and ROCKET AF studies. 
 
 
 
Table 3. Thromboembolic risk factors in the study participants (from the CRAFT, RE-LY [2] and ROCKET AF studies [3]) according to the 
treatment group. 
 VKA  Dabigatran 110 mg  Dabigatran 150 mg  Rivaroxaban 15 or 20 mg  
Variable 
CRAFT 
(n = 
1973) 
RE-LY (n 
= 6022) 
ROCKE
T AF (n 
= 7133) 
P* 
CRAFT 
(n = 187) 
RE-LY (n 
= 6015) 
P 
CRAFT (n = 
311) 
RE-LY (n 
= 6076) 
P 
CRAFT (n = 
1051) 
ROCKET AF 
(n = 7131) 
P 
Previous 
stroke or 
TIA 
219/1960 
(11.2) 
1195 
(19.8) 
3895 
(54.6) 
< 
0.0001 
< 
0.0001 
35/185 
(18.9) 
1195/6015 
(19.9) 0.74 24/309 (7.8) 1233 (20.3) < 0.0001 
168/1046 
(16.1) 
3916 (54.9) 
< 
0.0001 
CHADS2 
score 
1.9 ± 1.3, 
n = 1960 
2.1 ± 1.1 3.5 ± 1.0 
< 
0.0001 
< 
0.0001 
2.6 ± 1.2, 
n = 185 
2.1 ± 1.1 < 
0.0001 
1.3 ± 1.2, n = 
309 
2.2 ± 1.2 < 0.0001 
2.2 ± 1.4, n = 
1046 
3.5 ± 0.9 
< 
0.0001 
0–1 
886/1960 
(45.2) 
1859 
(30.9) 
– 
< 
0.0001 
32/185 
(17.3) 
1958/6014 
(32.6) 
< 
0.0001 
208/309 
(67.3) 
1958 (32.2) < 0.0001 
365/1046 
(34.9) 
–  
2 
475/1960 
(24.2) 
2230 
(37.0) 
934 
(13.1) 
< 
0.0001 
63/185 
(34.1) 
2088/6014 0.87 62/309 (20.1) 2137 (35.2) < 0.0001 
279/1046 
(26.7) 
925 (13.0) 
< 
0.0001 
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< 
0.0001 
(34.7) 
3–6 
599/1960 
(30.6) 
1933 
(32.1) 
6197 
(86.9) 
0.22 
< 
0.0001 
90/185 
(48.6) 
1968/6014 
(32.7) 
< 
0.0001 
39/309 (12.6) 1981 (32.6) < 0.0001 
402/1046 
(38.4) 
6205 (87.0) 
< 
0.0001 
Vascular 
disease** 
862/1960 
(44.0) 
968 (16.1) 
1724 
(24.2) 
<0.0001 
<0.0001 
106/185 
(57.3) 
1008/6015 
(16.8) 
< 
0.0001 
67/309 (21.7) 1029 (16.9) 0.03 
504/1046 
(48.2) 
1583 (22.2) 
< 
0.0001 
Heart 
failure 
709/1960 
(36.2) 
1922 
(31.9) 
4441 
(62.3) 
0.0004 
< 
0.0001 
99/185 
(53.5) 
1937/6015 
(32.2) 
< 
0.0001 
62/309 (20.1) 1934 (31.8) < 0.0001 
434/1046 
(41.5) 
4467 (62.6) 
<0.000
1 
Diabetes 
mellitus 
518/1960 
(26.4) 
1410 
(23.4) 
2817 
(39.5) 
0.01 
< 
0.0001 
49/185 
(26.5) 
1409/6015 
(23.4) 0.33 51/309 (16.5) 1402 (23.1) 0.01 
309/1046 
(29.5) 
2878 (40.4) 
< 
0.0001 
Hypertens
ion 
1407/1960 
(71.8) 
4750 
(78.9) 
6474 
(90.8) 
< 
0.0001 
< 
0.0001 
136/185 
(73.5) 
4738/6015 
(78.8) 0.08 
207/309 
(67.0) 
4795 (78.9) < 0.0001 
748/1046 
(71.5) 
6436 (90.3) 
< 
0.0001 
COPD 
160/1970 
(81.0) 
– 
743 
(10.4) 
< 
0.0001 
23/187 
(12.3) 
–  8/310 (2.6) –  
134/1050 
(12.8) 
754 (10.6) 0.03 
Continuous variables are presented as mean ± standard deviation or number and (percentage). 
CHADS — congestive heart failure, hypertension, age (≥ 75 years), diabetes mellitus, stroke or transient ischemic attack; COPD — chronic obstructive pulmonary disease; n 
— number; RE-LY — The Randomized Evaluation of Long-Term Anticoagulation Therapy; ROCKET — Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition 
Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; TIA — transient ischemic attack; VKA — vitamin K antagonist 
*First p-value, (written above) refers to the comparison of VKA patients from the CRAFT and RE-LY studies, second p-value (written below) refers to the comparison of 
patients from the CRAFT and ROCKET AF studies. 
**In the CRAFT study “Vascular disease” was defined as prior myocardial infarction, ischemic heart disease, peripheral artery disease or aortic plaque, while in the RE-LY 
and ROCKET AF studies only prior myocardial infarction was consider. 
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Figure 1. Flow chart of patient enrollment in the current analysis; bid — twice daily, CRAFT 
— MultiCentre expeRience in AFib patients Treated with OAC; pts — patients; VKA — 
vitamin K antagonists. 
Figure 2. Thromboembolic risk basing on CHADS2 score in different OAC groups. Results 
are shown as  mean value. *Significant difference (p<0.05) where observed for comparison of 
vitamin K antagonists (VKAs) patients from the CRAFT study with both RE-LY and 
ROCKET AF trials. 
 
 
 
